Viscosupplementation Billing: Matching J7318–J7333 Hyaluronan Products to 20610/20611 Without Denials

In viscosupplementation billing, every claim has two lines, and both must be right. First, the drug line needs the HCPCS code for the exact hyaluronan product, billed in that code’s unit, with its NDC. Then the procedure line needs 20610 for a landmark-guided knee injection, or 20611 when the record documents ultrasound guidance with a saved image.

Most hyaluronic acid injection billing denials trace back to one of four gaps: the wrong J-code for the product, units counted in syringes instead of milligrams, a missing JZ or EJ modifier, or a chart that doesn’t meet the Medicare LCD. So this viscosupplementation billing guide maps every current product to its code and walks through the claim line by line.

5 Steps to Match Hyaluronan Products to Codes

Follow these steps on every injection claim to avoid denials:

1. Find the J-code by brand in the table below, from J7318 to J7332.
2. Convert the dose to units using that code’s unit: per dose, 1 mg or 0.1 mg.
3. Pick the injection code: 20610 without imaging, 20611 with documented ultrasound guidance.
4. Add the modifiers: RT, LT or 50 on the injection, JZ on the drug, and EJ from the second injection on.
5. Confirm coverage first: an M17 diagnosis, three months of failed conservative care and six months since any prior series.

Viscosupplementation Billing Codes by Product

In viscosupplementation billing, the HCPCS code follows the brand, not the generic name, and the billing unit differs by code. Some codes bill per dose, while others bill per milligram, so one syringe can mean 1 unit or 60.

CMS deleted J7333, the former Visco-3 code, on March 31, 2021, so Visco-3 now bills under J7321. Code-to-product pairs come from the OHSU hyaluronan reference and the CMS HCPCS files. Also, always check the package insert for the milligrams in each syringe.

Unit errors are the costliest. For example, J7318 Durolane billed as 1 unit instead of 60, or J7320 GenVisc billed per syringe, underpays the drug by almost its full cost. With J7321 billing, the opposite happens when staff enter milligrams on a per-dose code.

CPT 20610 vs 20611 for the Injection

Both codes describe arthrocentesis, aspiration or injection of a major joint such as the knee. The only difference, however, is image guidance.

20610: Without Ultrasound

Use 20610 for a landmark-guided injection. If fluoroscopy guides the needle, report 77002 with it. However, never add ultrasound guidance code 76942 to 20610.

20611: With Ultrasound Guidance

Ultrasound guided knee injection billing uses 20611, which already includes the ultrasound. In addition, CPT requires a permanent recorded image and a written report of the guidance. As a result, a note that says only “ultrasound used” does not support 20611, and the claim should drop to 20610.

Medicare covers ultrasound or fluoroscopic guidance when the record shows why the patient needed it. In contrast, LCDs L39529 and L39260 do not cover CT, MRI and arthrography for needle guidance, as these Medicare plan criteria summarize.

Both Knees on the Same Day

For bilateral injections, Medicare expects 20610-50 or 20611-50 on one line, while some commercial plans want RT and LT on two lines. However, the drug never takes modifier 50. Instead, its units double to cover both knees, and some contractors ask for separate RT and LT drug lines.

Building the Drug Line: Units, NDC and Modifiers

The drug line carries more data than the procedure line, and payers edit every field.

NDC reporting for hyaluronan follows the standard format: the N4 qualifier, the 11-digit NDC in 5-4-2 form, a unit qualifier such as UN or ML, and the quantity. It then goes in the shaded area of item 24 on paper claims or the drug segment of electronic claims. In addition, the NDC must match the product actually injected, not a similar one from the same manufacturer.

Three drug modifiers do most of the work:

The UTHealth injection series guide confirms the EJ modifier rule: it marks each later injection in a series for a joint, so the payer can tie it to the first. RT and LT go on the procedure line, and on the drug line when the payer asks.

For example, here is a sample claim for the second Euflexxa injection in the left knee, with ultrasound guidance:

1. 20611-LT × 1, diagnosis M17.12 (primary osteoarthritis, left knee)
2. J7323-EJ-JZ × 1, same diagnosis, with the N4 NDC data

In contrast, the first injection of that series would carry J7323-JZ with no EJ.

What the LCD Requires Before Payment

Medicare sets the bar through its LCD: hyaluronic acid knee osteoarthritis injections qualify for payment only when the chart meets every criterion below. Many commercial plans also copy the same rules.

Diagnosis and Medical Necessity

The claim needs an M17 knee osteoarthritis diagnosis that matches the side treated: M17.0 for bilateral primary OA, or M17.11 and M17.12 for the right or left knee. Coders also use post-traumatic and secondary OA codes in M17.2 to M17.5, and our guide to left knee pain ICD-10 codes shows when a pain code is not enough.

The chart must show:

• Knee pain that limits activities such as walking or standing
• X-ray evidence of OA, such as joint space narrowing or osteophytes
• At least three months of failed conservative care, including exercise or physical therapy and simple analgesics or NSAIDs
• Failed or contraindicated steroid injections, under some contractors’ criteria
• Function measured with a standardized tool, so the chart can show later improvement

The Six-Month Rule and Prior Auth

Payers cover a repeat course only when symptoms return, the last series brought documented improvement and at least six months have passed. Starting early is one of Medicare’s most common hyaluronan denials. In addition, the practice must use one product for the whole series, within the injection count on its label.

Commercial plans often add prior authorization and preferred-product lists. Because most practices buy the drug before billing it, a denied claim leaves the practice paying for the syringe. Therefore, confirming coverage before the first injection protects that inventory. Our post on orthopedic billing compliance covers the audit side of these rules.

Viscosupplementation Billing Denials and Fixes

Staff can correct and resubmit most viscosupplementation billing denials as soon as the cause is clear.

If the same denial repeats across payers, the fix belongs in the charge template, not in rework. Our guide to orthopedic coding modifiers covers the modifier errors behind many of these.

Recover the Full Cost of Every Hyaluronan Injection

Clean viscosupplementation billing starts with the product in the syringe. Its brand picks the J-code, the code sets the unit, the NDC proves it, and the guidance method decides between 20610 and 20611. Then add JZ and EJ where they belong, and keep the LCD criteria in the chart before the first injection.

Because the practice pays for the drug up front, every denial is a direct loss. MBW RCM checks product, units, NDC and coverage on each injection series with its orthopedic billing services, so payers settle high-cost hyaluronan claims the way the practice billed them.

Viscosupplementation Billing FAQs